Biosimilars and Biologics in Medicare Part D: MedP…

Biosimilars and Biologics in Medicare Part D: MedPAC briefing deck Via @medicarepayment #pharma #biotech goo.gl/awzqFL

Medicaid rebates on generic drugs and new inflatio…

Medicaid rebates on generic drugs and new inflation adjustment. CMS issues clarification medicaid.gov/Medicaid-CHIP-… #pharma #Mylan #epipen

Drug Pricing Reform: Understanding Indication Spec…

Drug Pricing Reform: Understanding Indication Specific Pricing of Pharmaceuticals #pharma #biotech #drugs… twitter.com/i/web/status/7…

Drug Pricing Reform: Understanding Indication Spec…

Drug Pricing Reform: Understanding Indication Specific Pricing of Pharmaceuticals goo.gl/oM6V7w #pharma… twitter.com/i/web/status/7…

Biologics and Biosimilars: Backgrounder on FDA reg…

Biologics and Biosimilars: Backgrounder on FDA regulatory issues, price comparisons, approvals goo.gl/qG2Twj #biotech #pharma

RT @sacjai: Drug pricing controversy focuses us on…

RT @sacjai: Drug pricing controversy focuses us on enormous gap between public & #pharma industry self-perception mmm-online.com/features/pharm… #Mylan #EpiPen

RT @Behind_the_Pill: My latest post on #pharma #ge…

RT @Behind_the_Pill: My latest post on #pharma #genetherapy #pricing is up! Check it out at behindthepill.com/whats-a-gene-t…

Drug companies offer money back guarantees for hig…

Drug companies offer money back guarantees for high-cost, cutting-edge therapies #pharma #biotech flip.it/oLzNSO

FDA: Long list of guidance under development by Ce…

FDA: Long list of guidance under development by Center for Drug Evaluation and Research (CDER). goo.gl/qhY8fc #pharma

NIH final rule expanding clinical trial reporting…

NIH final rule expanding clinical trial reporting is at OMB. Reqs more info, adverse events sent to registry website #Pharma #FDA #Drugs